Current results as reference for future improvements in immunosuppression
The immunosuppressive drug regimen most commonly used for kidney transplant recipients during the last 10 years was a combination of cyclosporine with either steroids or azathioprine, or both. More recently, new immunosuppressive drugs, such as tacrolimus, mycophenolate and rapamycin have been intro...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Chapter/Article Conference Paper |
| Language: | English |
| Published: |
1999
|
| In: |
Immunosuppression under trial
Year: 1999, Pages: 3-9 |
| DOI: | 10.1007/978-94-011-4643-2_1 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/978-94-011-4643-2_1 Verlag, lizenzpflichtig, Volltext: https://link.springer.com/chapter/10.1007/978-94-011-4643-2_1 
|
| Author Notes: | G. Opelz, B. Döhler and T. Wujciak |
| Summary: | The immunosuppressive drug regimen most commonly used for kidney transplant recipients during the last 10 years was a combination of cyclosporine with either steroids or azathioprine, or both. More recently, new immunosuppressive drugs, such as tacrolimus, mycophenolate and rapamycin have been introduced and hopes were raised that these new medications would improve the success rate of kidney grafts. Experience with these new drugs is still limited and long-term follow up is currently not available. The present report provides an overview of results obtained with regimens that were considered `standard’ during the last 10 years. They should serve as a reference against which future improvements can be measured. |
|---|---|
| Item Description: | Gesehen am 19.02.2021 |
| Physical Description: | Online Resource |
| ISBN: | 9789401146432 |
| DOI: | 10.1007/978-94-011-4643-2_1 |